Comparative Pharmacology
Head-to-head clinical analysis: PROFERDEX versus TRIFERIC AVNU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROFERDEX versus TRIFERIC AVNU.
PROFERDEX vs TRIFERIC AVNU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PROFERDEX (iron dextran) is a colloidal solution of ferric hydroxide in complex with dextran, providing a source of iron for hemoglobin synthesis and erythropoiesis. Iron is incorporated into heme, which is essential for oxygen transport in red blood cells.
Triferic AVNU (ferric pyrophosphate citrate) is an iron replacement product that provides iron to hemoglobin synthesis without increasing circulating iron levels. It is taken up by transferrin and delivered to erythroid precursor cells for heme synthesis.
100 mg intramuscular or intravenous every 3 to 7 days; may increase to 200 mg per dose.
Triferic Avnu (ferric pyrophosphate citrate) is administered intravenously at a dose of 2 mg iron per liter of dialysate fluid, delivered during each hemodialysis session via the dialysate line.
None Documented
None Documented
Terminal half-life approximately 20-30 hours in patients with normal hepatic function; prolonged in hepatic impairment. Clinical context: supports every-3-week dosing.
Terminal half-life of ferric pyrophosphate citrate is approximately 6-8 hours in patients with iron deficiency. In patients with normal iron stores, half-life may be longer due to redistribution. The iron component is not eliminated but conserved.
Primarily fecal (biliary excretion of iron from degraded RBCs, about 80-90%); renal excretion negligible (<5% unchanged).
Renal excretion of iron is minimal (<5% of administered dose); most iron is incorporated into hemoglobin or stored as ferritin/hemosiderin. Biliary/fecal excretion is negligible.
Category C
Category C
Iron Replacement
Iron Replacement